Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

ABSTRACT:

Background & aims

Antibodies against tumor necrosis factor-α are widely used to treat patients with Crohn's disease (CD). This study compared the effectiveness of infliximab and adalimumab, the 2 most commonly used anti-tumor necrosis factor agents, in patients with CD.

Methods

We conducted a retrospective cohort study by using U.S. Medicare data from 2006 through 2010. Patients with CD who were new users of infliximab (n = 1459) or adalimumab (n = 871) after January 31, 2007, were included. Patients older than age 85 and those with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis were excluded. The primary outcome measures were disease persistence on therapy at week 26, surgery (including bowel resection, creation of an ostomy, or surgical tre

SUBMITTER: Osterman MT 

PROVIDER: S-EPMC3883891 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature